Abcam (ABCZY) Stock Rating Upgraded by Zacks Investment Research

Abcam (OTCMKTS:ABCZY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm currently has a $18.00 target price on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 9.31% from the stock’s previous close.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Shares of Abcam (OTCMKTS ABCZY) traded up $0.29 on Friday, reaching $16.47. 1,245 shares of the company’s stock traded hands, compared to its average volume of 843. Abcam has a 1-year low of $9.76 and a 1-year high of $16.15.

ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/19/abcam-abczy-stock-rating-upgraded-by-zacks-investment-research.html.

Get a free copy of the Zacks research report on Abcam (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply